DIA vs XBI
SPDR Dow Jones Industrial Average ETF vs SPDR S&P Biotech ETF
- • DIA has the lower expense ratio at 0.16% vs 0.35% for XBI.
- • DIA pays a higher dividend yield (1.42%).
Side-by-side metrics
| Metric | DIA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.16% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.42% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $42.72B | $8.30B |
YTD return | 4.28% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.87 | 1.09 |
P/E ratio | 23.68 | — |
Last price | $495.91 | $133.66 |
Inception | — | — |
Issuer | State Street | State Street |
DIA top holdings
| GS | The Goldman Sachs Group Inc | 11.45% |
| CAT | Caterpillar Inc | 11.03% |
| MSFT | Microsoft Corp | 5.05% |
| UNH | UnitedHealth Group Inc | 4.59% |
| AMGN | Amgen Inc | 4.29% |
| V | Visa Inc Class A | 4.09% |
| HD | The Home Depot Inc | 4.07% |
| AXP | American Express Co | 4.00% |
| SHW | Sherwin-Williams Co | 3.98% |
| JPM | JPMorgan Chase & Co | 3.88% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About DIA
DIA (SPDR Dow Jones Industrial Average ETF) is Tracks the 30-stock Dow Jones Industrial Average. Managed by State Street, the fund carries $42.7B in assets under management, an expense ratio of 0.16%, a dividend yield of 1.42%. Its largest holding is The Goldman Sachs Group Inc (GS), which represents 11.4% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 11.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.